271 related articles for article (PubMed ID: 19755158)
41. Incorporation and in vitro release of doxorubicin in thermally sensitive micelles made from poly(N-isopropylacrylamide-co-N,N-dimethylacrylamide)-b-poly(D,L-lactide-co-glycolide) with varying compositions.
Liu SQ; Tong YW; Yang YY
Biomaterials; 2005 Aug; 26(24):5064-74. PubMed ID: 15769542
[TBL] [Abstract][Full Text] [Related]
42. Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis.
Sharma A; Sharma S; Khuller GK
J Antimicrob Chemother; 2004 Oct; 54(4):761-6. PubMed ID: 15329364
[TBL] [Abstract][Full Text] [Related]
43. Polymeric nanoparticles of cholesterol-modified glycol chitosan for doxorubicin delivery: preparation and in-vitro and in-vivo characterization.
Yu JM; Li YJ; Qiu LY; Jin Y
J Pharm Pharmacol; 2009 Jun; 61(6):713-9. PubMed ID: 19505361
[TBL] [Abstract][Full Text] [Related]
44. Lactoferrin conjugated PEG-PLGA nanoparticles for brain delivery: preparation, characterization and efficacy in Parkinson's disease.
Hu K; Shi Y; Jiang W; Han J; Huang S; Jiang X
Int J Pharm; 2011 Aug; 415(1-2):273-83. PubMed ID: 21651967
[TBL] [Abstract][Full Text] [Related]
45. Chemotherapy of brain tumour using doxorubicin bound to surfactant-coated poly(butyl cyanoacrylate) nanoparticles: revisiting the role of surfactants.
Petri B; Bootz A; Khalansky A; Hekmatara T; Müller R; Uhl R; Kreuter J; Gelperina S
J Control Release; 2007 Jan; 117(1):51-8. PubMed ID: 17150277
[TBL] [Abstract][Full Text] [Related]
46. In vivo evaluation of a new polymer-lipid hybrid nanoparticle (PLN) formulation of doxorubicin in a murine solid tumor model.
Wong HL; Rauth AM; Bendayan R; Wu XY
Eur J Pharm Biopharm; 2007 Mar; 65(3):300-8. PubMed ID: 17156986
[TBL] [Abstract][Full Text] [Related]
47. Effects of surface modification on delivery efficiency of biodegradable nanoparticles across the blood-brain barrier.
Kulkarni SA; Feng SS
Nanomedicine (Lond); 2011 Feb; 6(2):377-94. PubMed ID: 21385139
[TBL] [Abstract][Full Text] [Related]
48. Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives.
Mundargi RC; Babu VR; Rangaswamy V; Patel P; Aminabhavi TM
J Control Release; 2008 Feb; 125(3):193-209. PubMed ID: 18083265
[TBL] [Abstract][Full Text] [Related]
49. Tumor necrosis factor alpha blocking peptide loaded PEG-PLGA nanoparticles: preparation and in vitro evaluation.
Yang A; Yang L; Liu W; Li Z; Xu H; Yang X
Int J Pharm; 2007 Feb; 331(1):123-32. PubMed ID: 17097246
[TBL] [Abstract][Full Text] [Related]
50. Influence of the surfactant concentration on the body distribution of nanoparticles.
Araujo L; Löbenberg R; Kreuter J
J Drug Target; 1999; 6(5):373-85. PubMed ID: 10342385
[TBL] [Abstract][Full Text] [Related]
51. Transport of saquinavir across human brain-microvascular endothelial cells by poly(lactide-co-glycolide) nanoparticles with surface poly-(γ-glutamic acid).
Kuo YC; Yu HW
Int J Pharm; 2011 Sep; 416(1):365-75. PubMed ID: 21736932
[TBL] [Abstract][Full Text] [Related]
52. Nanoparticle-mediated delivery of neurotoxin-II to the brain with intranasal administration: an effective strategy to improve antinociceptive activity of neurotoxin.
Ruan Y; Yao L; Zhang B; Zhang S; Guo J
Drug Dev Ind Pharm; 2012 Jan; 38(1):123-8. PubMed ID: 21721852
[TBL] [Abstract][Full Text] [Related]
53. Doxorubicin-loaded PLGA nanoparticles for the chemotherapy of glioblastoma: Towards the pharmaceutical development.
Maksimenko O; Malinovskaya J; Shipulo E; Osipova N; Razzhivina V; Arantseva D; Yarovaya O; Mostovaya U; Khalansky A; Fedoseeva V; Alekseeva A; Vanchugova L; Gorshkova M; Kovalenko E; Balabanyan V; Melnikov P; Baklaushev V; Chekhonin V; Kreuter J; Gelperina S
Int J Pharm; 2019 Dec; 572():118733. PubMed ID: 31689481
[TBL] [Abstract][Full Text] [Related]
54. Enhanced surface attachment of protein-type targeting ligands to poly(lactide-co-glycolide) nanoparticles using variable expression of polymeric acid functionality.
McCarron PA; Marouf WM; Donnelly RF; Scott C
J Biomed Mater Res A; 2008 Dec; 87(4):873-84. PubMed ID: 18228271
[TBL] [Abstract][Full Text] [Related]
55. Efficient chemotherapy of rat glioblastoma using doxorubicin-loaded PLGA nanoparticles with different stabilizers.
Wohlfart S; Khalansky AS; Gelperina S; Maksimenko O; Bernreuther C; Glatzel M; Kreuter J
PLoS One; 2011 May; 6(5):e19121. PubMed ID: 21573151
[TBL] [Abstract][Full Text] [Related]
56. Influence of surfactants, polymer and doxorubicin loading on the anti-tumour effect of poly(butyl cyanoacrylate) nanoparticles in a rat glioma model.
Ambruosi A; Gelperina S; Khalansky A; Tanski S; Theisen A; Kreuter J
J Microencapsul; 2006 Aug; 23(5):582-92. PubMed ID: 16980278
[TBL] [Abstract][Full Text] [Related]
57. The role of apolipoprotein E in uptake of atovaquone into the brain in murine acute and reactivated toxoplasmosis.
Shubar HM; Dunay IR; Lachenmaier S; Dathe M; Bushrab FN; Mauludin R; Müller RH; Fitzner R; Borner K; Liesenfeld O
J Drug Target; 2009 May; 17(4):257-67. PubMed ID: 19255896
[TBL] [Abstract][Full Text] [Related]
58. Transport of Poly(n-butylcyano-acrylate) nanoparticles across the blood-brain barrier in vitro and their influence on barrier integrity.
Rempe R; Cramer S; Hüwel S; Galla HJ
Biochem Biophys Res Commun; 2011 Mar; 406(1):64-9. PubMed ID: 21295549
[TBL] [Abstract][Full Text] [Related]
59. Formulation development and systematic optimization of solid lipid nanoparticles of quercetin for improved brain delivery.
Dhawan S; Kapil R; Singh B
J Pharm Pharmacol; 2011 Mar; 63(3):342-51. PubMed ID: 21749381
[TBL] [Abstract][Full Text] [Related]
60. Multivariate design for the evaluation of lipid and surfactant composition effect for optimisation of lipid nanoparticles.
Martins S; Tho I; Souto E; Ferreira D; Brandl M
Eur J Pharm Sci; 2012 Apr; 45(5):613-23. PubMed ID: 22245538
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
